Will Alten Be A Significant Clinical Trials CRO?

/ August 31, 2021

ER&D services largest pure-play, Alten, has ambitions as a clinical trials contract research organization (CRO). During Q2 2021, the company completed the acquisition of Cmed. Cmed, a clinical trial CRO based in the UK. It is a small firm with EUR 20m in revenues and 180 consultants. It has specialized in oncology, immuno-oncology, cell therapy, and rare disease.

Alten: A Big Rebound in Q2

/ August 18, 2021

Alten impressed investors with its Q2 rebound: revenues had a big rebound (+19.7% yoy at cc/cs) to EUR 714m. We had anticipated this solid rebound: the comps were very favorable (Q2 2020 was down 18.4% yoy organically).

Alten Makes its Largest Acquisition Ever, in Digital

/ November 15, 2020

Alten is to make its largest acquisition, with Milan-headquartered SDG Group. SDG has revenues of EUR 76m and a headcount of 950. Its operating margin is ~10%. We estimate the price paid by Alten to ~EUR 60m.

Europe Has Entered its Second Lockdown. A Look at Financial Implications

/ November 1, 2020

Europe has now entered its second lockdown. The lockdowns have different restrictions levels and different lengths. The UK and France are running for the full month of November. Officials in the two countries have, however, warned the lockdown might last longer, until Christmas at least.

Alten Accelerates its M&A Activity

/ September 30, 2020

Alten will accelerate its M&A activity in 2020. This is one of the tactical changes that the company announced during its H1 2020 results presentation. The company is also shifting its commercial effort to financial services, energy, and life science, and slightly accelerating its offshore deployment.

Unofficial: Renault Selects its Four ER&D Preferred Vendors

/ July 24, 2020

According to unofficial sources, Renault has now finalized its list of preferred ER&D service vendors, reducing it from nine vendors to four. The four winners are Akka, Bertrandt, Expleo, and Segula. They will now grab 80% of Renault’s ER&D spending and double their market shares.

Earnings Preview: Revenues of Alten to Plunge in Q2

/ July 15, 2020

ER&D’s largest pure-play globally, Alten, will be announcing its Q2 2020 revenue by the end of July. The company had a very decent Q1, with a 4% CC/CS revenue growth. However, it warned that revenues would be down by ~22% in Q2.

Alten Slows Down in Q4. Points to Market Adjustment

/ February 3, 2020

Alten’s revenues in Q4 slowed down to a growth of +7.3% yoy (at CC/CS ), following double-digit CC/CS growth during Q1-Q3 2019. The company suffered from a demanding comparison basis (+13.7% in Q4 2018), and one lesser working day in several countries (a 0.15% impact on the group’s revenues).

Alten: simply impressive!

/ September 22, 2019

The performance of Alten remained impressive in H1 2019: revenues were up 16.8% yoy at CC, and up 12.5% at CC/CS, reaching EUR 1,292m during the period.

Alten adds EUR 100m in revenues this quarter

/ April 28, 2019

Alten impressed, again, with its growth performance. In Q1 2019, revenue growth (at CC/CS yoy) reached +12.5%, to EUR 643m. This quarter, Alten added almost EUR 100m in revenues, two-thirds of it through organic growth and one third through acquisitions. The Forex impact was negligible.

Why onshore ER&D service vendors must pro-actively become India-centric

/ January 6, 2019

It is striking to see how few onshore ER&D service vendors have built a significant Indian or nearshore presence. Onshore vendors do acknowledge that the Indian ER&D service vendors grow faster than they do but argue that most of the Indian vendors service U.S. clients or industries (mostly, ISVs, technology vendors and telecom equipment manufacturers) they do not quite address.